Format

Send to

Choose Destination
Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2509-2514. doi: 10.1167/iovs.19-27099.

Nicotinamide Deficiency in Primary Open-Angle Glaucoma.

Author information

1
Equipe Mitolab, Unité Mixte de Recherche MITOVASC, CNRS 6015, INSERM U1083, Université d'Angers, Angers, France.
2
Département de Biochimie et Génétique, Centre Hospitalier Universitaire, Angers, France.
3
Département d'Ophtalmologie, Centre Hospitalier Universitaire, Angers, France.
4
Service de Biochimie, EA4650, Centre Hospitalier Universitaire, Caen, France.
5
Singapore Eye Research Institute, Singapore National Eye Centre, Duke-NUS, Singapore.

Abstract

Purpose:

To investigate the plasma concentration of nicotinamide in primary open-angle glaucoma (POAG).

Methods:

Plasma of 34 POAG individuals was compared to that of 30 age- and sex-matched controls using a semiquantitative method based on liquid chromatography coupled to high-resolution mass spectrometry. Subsequently, an independent quantitative method, based on liquid chromatography coupled to mass spectrometry, was used to assess nicotinamide concentration in the plasma from the same initial cohort and from a replicative cohort of 20 POAG individuals and 15 controls.

Results:

Using the semiquantitative method, the plasma nicotinamide concentration was significantly lower in the initial cohort of POAG individuals compared to controls and further confirmed in the same cohort, using the targeted quantitative method, with mean concentrations of 0.14 μM (median: 0.12 μM; range, 0.06-0.28 μM) in the POAG group (-30%; P = 0.022) and 0.19 μM (median: 0.18 μM; range, 0.08-0.47 μM) in the control group. The quantitative dosage also disclosed a significantly lower plasma nicotinamide concentration (-33%; P = 0.011) in the replicative cohort with mean concentrations of 0.14 μM (median: 0.14 μM; range, 0.09-0.25 μM) in the POAG group, and 0.19 μM (median: 0.21 μM; range, 0.09-0.26 μM) in the control group.

Conclusions:

Glaucoma is associated with lower plasmatic nicotinamide levels, compared to controls, suggesting that nicotinamide supplementation might become a future therapeutic strategy. Further studies are needed, in larger cohorts, to confirm these preliminary findings.

PMID:
31185090
DOI:
10.1167/iovs.19-27099

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center